Final results of a prospective study of scalp cooling in preventing chemotherapy-induced alopecia.

Autor: Orlando L; Medical Oncology Division, Antonio Perrino Hospital, Brindisi, Italy., Loparco D; Medical Oncology Division, Antonio Perrino Hospital, Brindisi, Italy., Fedele P; Medical Oncology Division, Antonio Perrino Hospital, Brindisi, Italy., Schiavone P; Medical Oncology Division, Antonio Perrino Hospital, Brindisi, Italy., Quaranta A; Medical Oncology Division, Antonio Perrino Hospital, Brindisi, Italy., Caliolo C; Medical Oncology Division, Antonio Perrino Hospital, Brindisi, Italy., Cinefra M; Medical Oncology Division, Antonio Perrino Hospital, Brindisi, Italy., Rizzo P; Medical Oncology Division, Antonio Perrino Hospital, Brindisi, Italy., Calvani N; Medical Oncology Division, Antonio Perrino Hospital, Brindisi, Italy., Morleo A; Medical Oncology Division, Antonio Perrino Hospital, Brindisi, Italy., Varriano R; Medical Oncology Division, Antonio Perrino Hospital, Brindisi, Italy., Bonuso V; Medical Oncology Division, Antonio Perrino Hospital, Brindisi, Italy., Falcone LL; Medical Oncology Division, Antonio Perrino Hospital, Brindisi, Italy., Caloro M; Medical Oncology Division, Antonio Perrino Hospital, Brindisi, Italy., Cinieri S; Medical Oncology Division, Antonio Perrino Hospital, Brindisi, Italy.
Jazyk: angličtina
Zdroj: Future oncology (London, England) [Future Oncol] 2019 Oct; Vol. 15 (29), pp. 3337-3344. Date of Electronic Publication: 2019 Oct 03.
DOI: 10.2217/fon-2019-0066
Abstrakt: Aim: Alopecia is a distressing effect of cancer treatments. Our study examined efficacy and safety of scalp cooling to prevent chemotherapy-induced alopecia. Materials & methods: Early breast cancer patients candidate to anthracycline and/or taxane were eligible. Dean's alopecia scale was used to classify alopecia. Results: From February 2016 to November 2018, 127 women were enrolled; 55 (43.3%) received epirubicin/cyclophosphamide (4 EC 3 weeks) followed by paclitaxel (12 P weeks); 50 (39.4%) received 4 EC 3 weeks; 20 (15.7%) received 12 P weeks/trastuzumab and 2 docetaxel/cyclophosphamide (4 TC 3 weeks). The success rate was 71.7% (G0 21.3%, G1 31.5%, G2 18.9%). Frequent side effects were: coldness, headache, scalp pain and head heaviness. Conclusion: In our study, scalp cooling can prevent alopecia thus supporting the wider use in early breast cancer.
Databáze: MEDLINE
Externí odkaz: